Month: September 2026

CALGARY, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American: GTE) (TSX:GTE) (LSE:GTE) today announced the results of its previously announced solicitation (the “Consent Solicitation”) of consents (the “Consents”) from Holders of its 9.750% Senior Secured Amortizing Notes due 2031 (the “Notes”) to effect certain proposed amendments (the “Proposed Amendments”) to the indenture dated as of February 18, 2026, under which the Notes were issued (the “Indenture”), pursuant to the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated September 11, 2026 (the “Consent Solicitation Statement”). Any capitalized terms used in this press release without definition have the respective meanings assigned to such terms in the Consent Solicitation Statement.

As previously announced, the Consent Solicitation was conducted in connection with the previously announced sale of Gran Tierra’s Colombian and Ecuadorian businesses to Maurel & Prom for total consideration of approximately $1.33 billion, subject to adjustment (the “Sale”), pursuant to the terms and conditions of the Share Sale and Purchase Agreement entered into on August 5, 2026.

As of September 22, 2026 and according to the information received by D.F. King & Co. Inc., consents to the Proposed Amendments had been provided and not validly revoked by holders of not less than 50% in aggregate principal amount of the Notes outstanding. Accordingly, the Company has obtained the consents required to effect the Proposed Amendments.

On September 22, 2026, the Company, the Note Guarantors and the Trustee executed a supplemental indenture (the “Supplemental Indenture”) to effect the Proposed Amendments in accordance with the Consent Solicitation Statement, dated as of September 11, 2026. The Supplemental Indenture became effective immediately upon execution but will only become operative on the closing date of the Sale, at which time it will be binding on all holders of the Notes, including those who did not deliver a consent at or prior to such execution. The consent fee payable to Holders who validly delivered (and did not validly revoke) their consents prior to the Expiration Time will be payable on the closing date of the Sale.

BofA Securities, Inc. served as sole Solicitation Agent in the Consent Solicitation and D.F. King & Co. Inc. served as the Information and Tabulation Agent. Persons with questions regarding the Consent Solicitation should contact BofA Securities, Inc. at (toll free) (888) 292-0070 or (collect) (646) 855-8988. Requests for the Consent Solicitation Statement should be directed to D.F. King & Co. Inc., at (toll free) (888) 548-6498, (banks and brokers) (646) 582-9168 or by email to gte@dfking.com.

This press release is not a solicitation of consents with respect to the Proposed Amendments or otherwise. The Consent Solicitation was made solely through the Consent Solicitation Statement referred to above and related materials. The Consent Solicitation was not made to Holders of Notes in any jurisdiction where the making of the Consent Solicitation would not be in compliance with the laws of such jurisdiction. Neither the Consent Solicitation Statement nor any documents related to the Consent Solicitation have been filed with, or approved or reviewed by, any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Consent Solicitation Statement or any documents related to the Consent Solicitation, and it is unlawful and may be a criminal offense to make any representation to the contrary.

Contact Information

For investor and media inquiries please contact:
Gary Guidry, Chief Executive Officer
Ryan Ellson, Executive Vice President & Chief Financial Officer
(403) 265-3221
info@grantierra.com

About Gran Tierra Energy Inc.

Gran Tierra Energy Inc., together with its subsidiaries, is an independent international energy company currently focused on oil and natural gas exploration and production in Canada, Colombia, Ecuador and Azerbaijan. Upon completion of the Sale described in this press release, the Company’s producing operations will be focused on Canada, and the Company will continue to pursue its exploration interests in Azerbaijan and additional new growth opportunities that would further strengthen the Company’s portfolio. The Company’s common stock trades on the NYSE American, the Toronto Stock Exchange and the London Stock Exchange under the ticker symbol GTE. Additional information concerning Gran Tierra is available at www.grantierra.com. Except to the extent expressly stated otherwise, information on the Company’s website or accessible from our website or any other website is not incorporated by reference into and should not be considered part of this press release. Investor inquiries may be directed to info@grantierra.com or (403) 265-3221.

Gran Tierra’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available on the SEC website at http://www.sec.gov. Gran Tierra’s Canadian securities regulatory filings are available on SEDAR+ at http://www.sedarplus.ca and UK regulatory filings are available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Forward Looking Statements and Legal Advisories:

This press release contains opinions, forecasts, projections, and other statements about future events or results that constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and financial outlook and forward looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”), which can be identified by such terms as “expect,” “plan,” “can,” “will,” “should,” “guidance,” “estimate,” “forecast,” “intend,” “anticipate,” “believes,” and “remains subject to,” derivations thereof and similar terms are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, the satisfaction of the conditions precedent to, and the timing of the completion of, the Sale and the expected closing date of the Sale.

The forward-looking statements contained in this press release are based on certain assumptions made by Gran Tierra based on management’s experience and other factors believed to be appropriate. Gran Tierra believes these assumptions to be reasonable at this time, but the forward-looking statements are subject to risks and uncertainties, many of which are beyond Gran Tierra’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. All forward-looking statements are made as of the date of this press release and the fact that this press release remains available does not constitute a representation by Gran Tierra that Gran Tierra believes these forward-looking statements continue to be true as of any subsequent date. Actual results may vary materially from the expected results expressed in forward-looking statements. Gran Tierra disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Important Information Regarding the Sale

This press release is neither a solicitation of a proxy nor an offer to purchase nor a solicitation of an offer to sell any securities. This press release is also not a substitute for any proxy statement or other filings that may be made with the SEC with respect to the Sale. The Company has filed a definitive proxy statement with the SEC to be used to solicit stockholder approval of the transaction. Detailed information about the Sale is contained in the definitive proxy statement and other documents filed with the SEC and disseminated to stockholders prior to the meeting.

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026.

About LifeMD, Inc.

LifeMD® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact
ir@lifemd.com

Media Contact
press@lifemd.com

Provides information in connection with early warning requirements under applicable Canadian securities laws.

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Limited (“Xanadu“; NASDAQ/TSX: XNDU), a leading photonic quantum computing company, today announced the addition of a strategic leader to its executive team: Tara Deakin as Chief People Officer. This appointment strengthens Xanadu’s leadership as it continues to scale and advance its mission to build quantum computers that are useful and available to people everywhere. As part of this planned transition, current Chief People Officer Rebecca Laramée will continue with the company as Senior Vice President of Human Resources, where she will partner with Deakin to lead Xanadu’s high-growth workforce initiatives.

“Tara is an outstanding addition to our leadership team,” said Dr. Christian Weedbrook, Founder and Chief Executive Officer of Xanadu. “As we continue towards our vision of building a utility-scale, fault-tolerant quantum computer, her extensive experience in global enterprise transformation, leadership effectiveness, and aligning human capital with business strategy will be invaluable in scaling our organization with discipline and purpose. We are also immensely grateful to Rebecca for her leadership as Chief People Officer, and we look forward to her continued impact as Senior Vice President of Human Resources as we build out our global team.”

Deakin brings extensive experience leading people and organizational strategy through periods of growth and transformation. Prior to joining Xanadu, she served as Chief People Officer and Executive Vice President at Spin Master, where she had global responsibility for people strategy, corporate communications, real estate and workplace experience. During her tenure, helped guide the organization as it expanded globally, entered new product categories through organic growth and acquisition, and became increasingly complex — building on the strengths that drove its success while evolving its leadership, organization and ways of working for its next stage.

Over the course of her career, Deakin has held executive leadership roles spanning human resources, operations, talent and enterprise strategy at Spin Master, TD Bank Group, Citi and Rogers Communications. She also serves as an independent director and Chair of the Human Resources Committee of goeasy Ltd.

“Xanadu is building something truly extraordinary, and I’m excited to join at such an important point in the company’s evolution,” said Tara Deakin. “I look forward to partnering with Christian, Rebecca, and the broader team to build the organizational and leadership capabilities that will support Xanadu’s next stage of growth and advance the company’s mission to build quantum computers that are useful and available to people everywhere.”

Early Warning Reporting

The following information is being provided by Dr. Weedbrook in connection with the early warning requirements under applicable Canadian securities laws. On September 22, 2026, Dr. Weedbrook disposed of an aggregate of 4,600,000 Class B Subordinate Voting Shares of Xanadu (“Class B Subordinate Voting Shares”) through sales on the Toronto Stock Exchange (the “TSX”) and other published markets (the “Sale”). In connection with the Sale, Dr. Weedbrook converted an aggregate 4,600,000 Class A Multiple Voting Shares of Xanadu (“Class A Multiple Voting Shares”, together with the Class B Subordinate Voting Shares, the “Company Shares”) into Class B Subordinate Voting Shares on a one-for-one basis (the “Conversion”).

Prior to the Conversion and Sale, Dr. Weedbrook held 46,432,704 Class A Multiple Voting Shares and 8,906 Class B Subordinate Voting Shares, representing approximately 19.5% of total issued and outstanding Class A Multiple Voting Shares, less than 1% of total issued and outstanding Class B Subordinate Voting Shares, approximately 15.24% of the total issued and outstanding Company Shares and approximately 18.97% of total voting power attached to the Company Shares. The Class A Multiple Voting Shares converted represented approximately 2.98% of total issued and outstanding Class A Multiple Voting Shares and the Class B Subordinate Voting Shares sold pursuant to the Sale represented approximately 3.05% of total issued and outstanding Class B Subordinate Voting Shares. Following the Conversion and Sale, Dr. Weedbrook held 41,832,704 Class A Multiple Voting Shares and 18,593 Class B Subordinate Voting Shares, representing approximately 27.6% of total issued and outstanding Class A Multiple Voting Shares, less than 1% of total issued and outstanding Class B Subordinate Voting Shares, approximately 13.71% of the total issued and outstanding Company Shares and approximately 25.06% of total voting power attached to the Company Shares. If all of the Class A Multiple Voting Shares held by Dr. Weedbrook were converted into Class B Subordinate Voting Shares in accordance with their terms, Dr. Weedbrook would hold 41,851,297 Class B Subordinate Voting Shares, representing approximately 21.70% of Class B Subordinate Voting Shares then issued and outstanding and approximately 3.18% of total voting power attached to the Company Shares.

The securities were sold through the facilities of the TSX and other published markets. A total of 4,041,659 shares were sold in Canada at prices ranging from C$7.00 to C$9.25. A total of 558,341 shares were sold in the U.S. at prices ranging from US$5.01 to US$7.27 (C$7.024521 to C$10.193267 based on the USD:CAD Bank of Canada exchange rate on September 21, 2026). Aggregate gross proceeds of approximately C$32,831,120.00. The shares were sold by Dr. Weedbrook pursuant to the Sale for personal financial planning purposes.

As an executive officer of Xanadu and member of the board of the directors of Xanadu, Dr. Weedbrook is actively involved in Xanadu’s business, operations and planning. Except as disclosed herein, Dr. Weedbrook does not have any present plans or proposals which relate to or that would result in any of the actions or transactions described in paragraphs (a) through (k) of Item 5 of Form 62-103F1 to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. Dr. Weedbrook may, however, increase or decrease his registered or beneficial ownership of, or control over, the Class A Multiple Voting Shares, Class B Subordinate Voting Shares or other securities of Xanadu, directly or indirectly, in the future, in the open market, in privately-negotiated purchases, through the conversion of Class A Multiple Voting Shares into Class B Subordinate Voting Shares or otherwise, depending on, among other things, Xanadu’s business and prospects, market and general economic conditions and other available investment opportunities, subject to applicable laws and the terms of the Xanadu’s Articles of Incorporation (as amended), Investor and Registration Rights Agreement and Coattail Agreement, each as described in Xanadu’s Annual Information Form dated March 31, 2026.

The head office of Xanadu and the address for Dr. Weedbrook are 777 Bay Street, Suite 2400, Toronto, Ontario, Canada, M5G 2C8. For further information (including a copy of the early warning reports to be filed with securities regulators in connection with this press release), please see Xanadu’s profile on SEDAR+ at www.sedarplus.ca or telephone Natalie Wilmore at 416-304-9629.

About Xanadu

Founded in 2016, Xanadu is a Canadian photonic quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Xanadu is building fault-tolerant quantum computers using light, with systems designed to compute at room temperature. Xanadu develops both hardware and software, including PennyLane, its open-source quantum computing platform. Xanadu is the first pure-play photonic quantum computing company to list on public markets (Nasdaq/TSX: XNDU) and is recognized globally for its breakthroughs in scalable quantum technologies. Visit xanadu.ai or follow on X @XanaduAI.

Contacts

Press Contact: press@xanadu.ai 

Investor Relations: investors@xanadu.ai 

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. We have based these forward-looking statements on current expectations and projections about future events. These statements include: the executive appointment of Tara Deakin as Chief People Officer and the role transition of Rebecca Laramée to Senior Vice President of Human Resources; the expected impacts of such leadership appointments on Xanadu’s enterprise transformation, leadership effectiveness, organizational scaling, high-growth workforce initiatives, high-performance culture, and talent pipeline; information regarding Dr. Weedbrook’s securityholdings and related intentions; the expected advancement of Xanadu’s vision to build a utility-scale, fault-tolerant quantum computer; and Xanadu’s mission to build quantum computers that are useful and available to people everywhere.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of Xanadu. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the actual results of Xanadu, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: the risk that executive transitions may cause operational disruptions or fail to achieve intended organizational objectives; Xanadu’s ability to successfully integrate new executive leadership and retain key personnel during transitions; challenges in scaling workforce initiatives and talent pipelines to support accelerated growth; that Xanadu is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; Xanadu’s historical net losses and limited operating history; that there is substantial doubt about Xanadu’s ability to continue as a going concern; Xanadu’s expectations regarding future financial performance, capital requirements and unit economics; Xanadu’s use and reporting of business and operational metrics; Xanadu’s competitive landscape; Xanadu’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; Xanadu’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; Xanadu’s reliance on strategic partners and other third parties; Xanadu’s concentration of revenue in contracts with government or state-funded entities; Xanadu’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption, and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; material weaknesses in Xanadu’s internal control over financial reporting and its ability to maintain internal control over financial reporting and operate as a public company; the outcome of any legal proceedings or government investigations that may be commenced against Xanadu; Xanadu’s ability to issue equity or equity-linked securities in the future; and other factors described in Xanadu’s filings with the SEC (www.sec.gov) and the Canadian Securities Administrators (www.sedarplus.com). These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by Xanadu with the SEC and the Canadian Securities Administrators, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of Xanadu’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While Xanadu may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.

The Company is also pleased to announce that, effective October 1, 2026, the Company’s legal name will be changed from “Cybin Inc.” to “Helus Pharma Inc.”. The legal name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.

1. Appointment of Auditor

Zeifmans LLP was appointed auditor of Helus until the next annual meeting of shareholders at renumeration to be fixed by the directors of Helus. Voting results are set out below:

Votes For		Votes Withheld
#	%	#	%
46,084,004	99.207	368,593	0.793

2. Number of Directors

The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For		Votes Against
#	%	#	%
46,139,333	99.326	313,263	0.674

3. Name Change

The special resolution to change the name of the Company from “Cybin Inc.” to “Helus Pharma Inc.” or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For		Votes Against
#	%	#	%
46,134,602	99.315	317,994	0.685

4. Election of Directors

Each of the nominees for election as director listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

	Votes For		Votes Withheld
	#	%	#	%
Theresa Firestone	31,992,429	99.239	245,371	0.761
Grant Froese	32,147,160	99.719	90,640	0.281
Paul Glavine	23,072,248	71.569	9,165,552	28.431
Michael Halstead	23,089,890	71.624	9,147,910	28.376
Eric Hoskins	30,895,235	95.835	1,342,565	4.165
Mark Lawson	32,156,082	99.747	81,718	0.253
Freda Lewis-Hall	23,063,327	71.541	9,174,473	28.459
Eric So	22,795,634	71.321	9,166,471	28.679

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to transform from a clinical stage discovery and development company to a commercial-ready pharmaceutical company; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Company’s performance and operations.

Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
‍
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com

Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
vverdeja@rxmedyn.com